

NovaSterilis Appoints Thomas E. Steffie to Head Business Development Effort

ITHACA, NY, April 25, 2008 – **NovaSterilis Inc.** has named Mr. Thomas E. Steffie as Vice President of Business Development. The company, a privately held biotechnology firm in Ithaca, NY, develops and commercializes proprietary supercritical carbon dioxide-based products and technologies for the sterilization of biomedical materials.

A twenty year veteran of the pharmaceutical industry, Mr. Steffie is an expert in managed care and government health policies involving infectious disease and transplant medicine. Prior to joining **NovaSterilis**, Mr. Steffie was employed at the Novartis Corporation, most recently as Associate Director of Health Policy. In that capacity he was responsible for all federal health policy issues affecting the infectious disease, transplant and immunology franchises at Novartis, including Medicare Part B and Part D, Medicaid (federal) and other government regulations. Mr. Steffie also spearheaded Novartis initiatives in health information technology, clinical research policies, Veterans Administration/Department of Defense, generic pharmaceuticals and biosimilars, valuebased benefit design, and chronic care management.

As Associate Director of Managed Healthcare Policy at Novartis between 2002 and 2006, Steffie managed all federal reimbursement policies affecting organ transplantation, as well as all state issues involving organ transplant medication access or reimbursement. During

that time he was named a Novartis Ambassador, and was the recipient of the company's Excellence Award for Ethics and Compliance 2005 as well as Business Excellence Awards in 2003 and 2004. Mr. Steffie began his career at Sandoz in 1987, prior to its merger with Ciba-Geigy Corporation to form Novartis, and he specialized in the marketing and sales of immunology, transplantation medicine and tissue engineering products.

"Tom Steffie has an unparalleled knowledge of the tissue engineering and transplant medicine markets," said **Mr. David Burns, CEO of NovaSterilis**. "That knowledge will be invaluable in his new position where he will assist us in establishing and executing on our company's longer-term strategic initiatives."

Mr. Steffie will assist **NovaSterilis** in launching new products for the medical sterilization markets. The company's Nova2200™ sterilization system represents the most advanced method of tissue sterilization currently in use.